MaxCyte, Inc. Grant of options (0971B)

TIDMMXCT

RNS Number : 0971B

MaxCyte, Inc.

14 June 2016

MaxCyte, Inc.

("MaxCyte" or the "Company")

Grant of Options

Maryland, USA - MaxCyte (LSE: MXCT), an established and revenue generating US-based developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, announces that it granted, effective of today, options over a total of 709,900 common stock of $0.01 per share in the Company ("Common Stock") to certain directors and applicable employees of the Company ("Option Grants"). Details of the Option Grants are given below:

 
                                                    Resulting 
                       Number of     Exercise    total number 
                         options    price per      of options 
 Individual              granted       option     outstanding 
--------------------  ----------  -----------  -------------- 
 Doug Doerfler, 
  CEO                    296,000       81.50p       1,841,080 
--------------------  ----------  -----------  -------------- 
 Ron Holtz, CFO          134,800       81.50p         790,092 
--------------------  ----------  -----------  -------------- 
 Madhusudan Peshwa, 
  CSO                    136,100       81.50p         916,393 
--------------------  ----------  -----------  -------------- 
 Stark Thompson, 
  NED                     20,400       81.50p         213,733 
--------------------  ----------  -----------  -------------- 
 Art Mandell, NED         20,400       81.50p          20,400 
--------------------  ----------  -----------  -------------- 
 Stan Erck, NED           20,400       81.50p         163,467 
--------------------  ----------  -----------  -------------- 
 Will Brooke, NED         40,900       81.50p          40,900 
--------------------  ----------  -----------  -------------- 
 John Johnston, 
  NED                     40,900       81.50p          40,900 
--------------------  ----------  -----------  --------------

Option Grants vest ratably on a monthly basis following grant (i) for Doug Doerfler, Ron Holtz and Madhusudan Peshwa, over 48 months, (ii) for Will Brooke and John Johnston, over 36 months, and (iii) for Stan Erck, Art Mandell and Stark Thompson, over 12 months. The Option Grants have an exercise period of 10 years from date of grant, at which time they will expire.

Certain other employees and one consultant have received Option Grants over a total of 392,300 Common Stock, effective of today, at an exercise price of 81.50p per option, which have an exercise period of 10 years.

- Ends -

For further information please contact:

 
 MaxCyte                                +1 301 944 1660 
 Doug Doerfler, Chief Executive 
  Officer 
  Ron Holtz, Chief Financial 
  Officer 
 
 Nominated Adviser and Broker 
  Panmure Gordon 
  Freddy Crossley (Corporate 
  Finance) 
  Fabien Holler 
  Duncan Monteith 
  Tom Salvesen (Corporate Broking)      +44 (0) 20 7886 2500 
 Financial PR Advisor                   +44 (0)203 709 5700 
  Consilium Strategic Communications     maxcyte@consilium-comms.com 
 Mary-Jane Elliott 
  Chris Welsh 
  Lindsey Neville

About MaxCyte

MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of cell-based medicines.

MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, commercial and clinical grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers with an established regulatory path.

MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies in a number of cancer indications, including solid tumors.

For more information visit http://www.maxcyte.com/

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHEASKLFSXKEEF

(END) Dow Jones Newswires

June 14, 2016 02:01 ET (06:01 GMT)

Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024